Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance

Por Chen, Zhao, Akbay, Esra, Mikse, Oliver, Tupper, Tanya, Cheng, Katherine, Wang, Yuchuan, Tan, Xiaohong, Altabef, Abigail, Woo, Sue-Ann, Chen, Liang, Reibel, Jacob B., Janne, Pasi A., Sharpless, Norman E., Engelman, Jeffrey A., Shapiro, Geoffrey I., Kung, Andrew L., Wong, Kwok-Kin
Publicado em 2013

Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation

Por Yang, Shenghong, Imamura, Yu, Jenkins, Russell W., Cañadas, Israel, Kitajima, Shunsuke, Aref, Amir, Brannon, Arthur, Oki, Eiji, Castoreno, Adam, Zhu, Zehua, Thai, Tran, Reibel, Jacob, Qian, Zhirong, Ogino, Shuji, Wong, Kwok K., Baba, Hideo, Kimmelman, Alec C., Di Magliano, Marina Pasca, Barbie, David A.
Publicado no Cancer Immunol Res (2016)

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

Por Xu, Chunxiao, Fillmore, Christine M., Koyama, Shohei, Wu, Hongbo, Zhao, Yanqiu, Chen, Zhao, Herter-Sprie, Grit S., Akbay, Esra A., Tchaicha, Jeremy H., Altabef, Abigail, Reibel, Jacob B., Walton, Zandra, Ji, Hongbin, Watanabe, Hideo, Jänne, Pasi A., Castrillon, Diego H., Rustgi, Anil K., Bass, Adam J., Freeman, Gordon J., Padera, Robert F., Dranoff, Glenn, Hammerman, Peter S., Kim, Carla F., Wong, Kwok-Kin
Publicado em 2014

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

Por Akbay, Esra A, Koyama, Shohei, Carretero, Julian, Altabef, Abigail, Tchaicha, Jeremy H, Christensen, Camilla L, Mikse, Oliver R, Cherniack, Andrew D, Beauchamp, Ellen M, Pugh, Trevor J, Wilkerson, Matthew D, Fecci, Peter E, Butaney, Mohit, Reibel, Jacob B, Soucheray, Margaret, Cohoon, Travis J, Janne, Pasi A, Meyerson, Matthew, Hayes, D. Neil, Shapiro, Geoffrey I, Shimamura, Takeshi, Sholl, Lynette M, Rodig, Scott J, Freeman, Gordon J, Hammerman, Peter S, Dranoff, Glenn, Wong, Kwok-Kin
Publicado em 2013

Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer

Por Zhang, Haikuo, Qi, Jun, Reyes, Jaime M., Li, Lewyn, Rao, Prakash K., Li, Fugen, Lin, Charles Y., Perry, Jennifer A., Lawlor, Matthew A., Federation, Alexander, De Raedt, Thomas, Li, Yvonne Y., Liu, Yan, Duarte, Melissa A., Zhang, Yanxi, Herter-Sprie, Grit S., Kikuchi, Eiki, Carretero, Julian, Perou, Charles M., Reibel, Jacob B., Paulk, Joshiawa, Bronson, Roderick T., Watanabe, Hideo, Fillmore, Christine M., Kim, Carla F., Hammerman, Peter S., Brown, Myles, Cichowski, Karen, Long, Henry, Bradner, James E., Wong, Kwok-Kin
Publicado no Cancer Discov (2016)

Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit

Por Zhu, Zehua, Aref, Amir R., Cohoon, Travis J., Barbie, Thanh U., Imamura, Yu, Yang, Shenghong, Moody, Susan E., Shen, Rhine R., Schinzel, Anna C., Thai, Tran C., Reibel, Jacob B., Tamayo, Pablo, Godfrey, Jason T., Qian, Zhi Rong, Page, Asher N., Maciag, Karolina, Chan, Edmond M., Silkworth, Whitney, Labowsky, Mary T., Rozhansky, Lior, Mesirov, Jill P., Gillanders, William E., Ogino, Shuji, Hacohen, Nir, Gaudet, Suzanne, Eck, Michael J., Engelman, Jeffrey A., Corcoran, Ryan B., Wong, Kwok-Kin, Hahn, William C., Barbie, David A.
Publicado em 2014